Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience (vol 41, pg 625, 2018)-MedSci.cn

Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience (vol 41, pg 625, 2018)

Marcinak, JF; Munsaka, MS; Watkins, PB; Ohira, T; Smith, N

Marcinak, JF (reprint author), Takeda Dev Ctr Amer Inc, Takeda Pharmaceut, 1 Takeda Pkwy, Deerfield, IL 60015 USA.

DRUG SAFETY, 2018; 41 (12): 1431

科室
- - 订阅+
  - 更多科室
工具
服务